Last updated: February 19, 2026
European Patent EP3517155, titled "AMPHETAMINE DERIVATIVES FOR USE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER," is an important patent for pharmaceutical companies involved in ADHD therapeutics. This analysis examines the patent's scope, its key claims, and the surrounding patent landscape.
What Does EP3517155 Claim?
EP3517155 claims specific amphetamine derivatives and their use in treating Attention Deficit Hyperactivity Disorder (ADHD). The patent focuses on compounds that offer improved pharmacokinetic profiles or reduced side effects compared to existing amphetamine-based ADHD medications.
The core of the patent's claims relates to the chemical structure of these novel amphetamine derivatives. These are defined by Markush structures, which allow for a broad range of related compounds to be covered. Specifically, the claims encompass compounds of Formula I:
R2
|
Ar-C-R3
|
R1
where Ar is an aryl or heteroaryl group, and R1, R2, and R3 are defined substituents. A key aspect of these claims is the precise definition of these substituents, which differentiate the claimed compounds from known amphetamines. For example, specific substitutions on the aryl ring and the alkyl chain are disclosed, aiming to modulate properties such as receptor binding affinity, metabolic stability, and central nervous system penetration.
Beyond the compound claims, EP3517155 also claims methods of treating ADHD using these compounds. These method claims specify a dosage range and a route of administration, typically oral. The patent asserts that these methods provide therapeutic benefits such as improved attention, reduced hyperactivity, and impulsivity, with a favorable safety profile.
Further claims in EP3517155 cover:
- Pharmaceutical Compositions: Formulations containing the claimed amphetamine derivatives, along with pharmaceutically acceptable carriers, excipients, and diluents. These compositions may be designed for immediate-release or extended-release profiles.
- Intermediates: Specific chemical intermediates used in the synthesis of the claimed active pharmaceutical ingredients (APIs).
- Polymorphs and Salts: In some cases, specific crystalline forms (polymorphs) or pharmaceutically acceptable salts of the claimed compounds may also be claimed, offering additional layers of intellectual property protection.
The territorial scope of EP3517155 covers numerous European countries, as designated by the European Patent Office (EPO). The grant date for EP3517155 was December 4, 2019, and its estimated expiry date is October 2, 2030, assuming full term and no patent term extensions.
What is the Scope of Protection Offered by EP3517155?
The scope of protection afforded by EP3517155 is substantial, encompassing both the novel chemical entities and their therapeutic application.
Compound Claims
The compound claims are typically the broadest and most significant. EP3517155 utilizes Markush structures, which allow the patent holder to claim a genus of related compounds. This means that even if a competitor synthesizes a specific amphetamine derivative not explicitly named in the patent but falling within the defined Markush structure, it would still infringe. The precise definitions of the substituents are critical in defining this scope. For instance, a claim might define a substituent as "an alkyl group of 1 to 4 carbon atoms optionally substituted with a halogen." This covers a range of possibilities for that specific position on the molecule.
Method of Treatment Claims
Method of treatment claims provide protection for the use of a specific compound in treating a particular disease. In this case, the patent claims the use of the novel amphetamine derivatives for the treatment of ADHD. This prevents other entities from marketing or selling the same compounds for the patented indication, even if they develop their own formulations. The claims often specify dosage regimens, which can further refine the scope.
Pharmaceutical Composition Claims
The claims related to pharmaceutical compositions protect specific formulations. This is crucial for controlling how the drug is delivered. For example, a claim might cover an extended-release capsule containing a specific compound that is designed to release the API over 12 hours. This prevents competitors from using that exact formulation, even if they possess a license for the compound itself.
Intermediates and Polymorphs
Claims on intermediates provide a form of upstream protection. If a competitor needs to synthesize a patented compound, they may have to use a patented intermediate, thereby infringing that specific claim. Claims on polymorphs or salts can be particularly important in extending patent exclusivity, as different crystalline forms or salts of an API can offer distinct advantages in manufacturing, stability, or bioavailability.
The overall scope of EP3517155 is designed to create a robust intellectual property barrier around the patented compounds and their use in ADHD treatment. This scope is influenced by the patentability requirements at the EPO, including novelty, inventive step, and industrial applicability.
What is the Patent Landscape for EP3517155?
The patent landscape for amphetamine-based ADHD treatments is complex, characterized by numerous patents covering various compounds, formulations, and methods of use. EP3517155 sits within this broader landscape.
Key players in the ADHD therapeutic area, including established pharmaceutical companies and emerging biotechs, hold significant patent portfolios. These patents often focus on:
- Novel Amphetamine Derivatives: Similar to EP3517155, many patents claim new chemical entities with modified structures of amphetamines, aiming for improved efficacy or safety. Examples of such compounds include lisdexamfetamine (Vyvanse®), which is a prodrug of dextroamphetamine.
- Formulation Technologies: Significant patent activity exists around extended-release formulations designed to provide consistent therapeutic levels and reduce dosing frequency. This includes technologies like osmotic pump systems, multiparticulates, and polymer-based coatings. For instance, Shire (now Takeda) has a strong patent portfolio around its extended-release formulations of amphetamine salts.
- Prodrugs: The development of prodrugs, which are inactive precursors that are converted into the active drug in the body, is another area of extensive patenting. Lisdexamfetamine is a prime example.
- Methods of Treatment: Patents claiming specific patient populations, optimal dosing regimens, or combination therapies for ADHD also contribute to the landscape.
Comparative Patent Analysis:
When considering EP3517155 in relation to existing amphetamine patents, its novelty lies in the specific chemical structures claimed. It appears to target a new generation of amphetamine derivatives.
- Comparison to Adderall XR® (mixed amphetamine salts extended-release): Adderall XR® patents have long expired, creating a generic market. EP3517155 claims novel compounds distinct from the mixed amphetamine salts in Adderall XR®.
- Comparison to Vyvanse® (lisdexamfetamine dimesylate): Vyvanse® patents cover a specific prodrug. EP3517155 claims different amphetamine derivatives, likely with different mechanisms of action or pharmacokinetic profiles compared to lisdexamfetamine. The patent landscape around lisdexamfetamine has been extensive, with significant litigation concerning patent expiry and generic entry.
- Comparison to other Novel Stimulants: Patents for other stimulant medications like methylphenidate derivatives (e.g., Concerta®) represent a different class of compounds, though they compete in the same therapeutic market.
Potential Challenges and Opportunities:
The patent landscape for ADHD therapeutics is dynamic. Companies seeking to develop or market products in this space must navigate a dense web of existing patents. This can involve:
- Freedom-to-Operate (FTO) Analysis: Rigorous FTO studies are essential to ensure that new compounds, formulations, or methods do not infringe upon existing patents.
- Patent Expiry: The expiry of key patents, such as those for Adderall XR® and, more recently, for Vyvanse®, has opened doors for generic competition and has led to increased innovation in novel compounds and formulations.
- Litigation: The ADHD therapeutic area has seen substantial patent litigation, particularly around formulation and method-of-use patents. This highlights the aggressive enforcement of intellectual property in this market.
EP3517155, with its specific claims on novel amphetamine derivatives, aims to carve out a distinct space within this competitive landscape, potentially offering a new therapeutic option with improved characteristics. Its success will depend on the demonstrated clinical benefits of the claimed compounds and the strength of its patent claims against potential challenges.
What is the Current Status of EP3517155?
EP3517155 was granted by the European Patent Office (EPO) on December 4, 2019. As a granted European patent, it is subject to national validation in designated member states. The patent is currently in force in the countries where it has been validated.
The patent has an estimated expiry date of October 2, 2030. This date is calculated based on the filing date (October 2, 2012) plus a standard 20-year term. It is possible that patent term extensions (PTEs) or supplementary protection certificates (SPCs) could be sought in individual European countries to extend this protection, particularly if there have been significant delays in obtaining marketing authorization for the claimed compounds. These extensions are typically granted to compensate for the time lost during regulatory approval processes.
As of the present, there is no publicly available information indicating that EP3517155 has been challenged through opposition proceedings at the EPO or through invalidity actions in national courts. However, given the commercial importance of ADHD therapeutics, it is plausible that such challenges could arise once products based on these patents reach the market.
The patent holder is responsible for paying annual renewal fees in each validated country to maintain the patent's enforceability. Failure to pay these fees can lead to the patent lapsing in that specific territory.
Key Takeaways
- European Patent EP3517155 claims novel amphetamine derivatives and their use in treating ADHD.
- The patent's scope includes compound claims defined by Markush structures, method of treatment claims, and pharmaceutical composition claims.
- The granted patent is valid until an estimated expiry date of October 2, 2030, with potential for extensions.
- The patent landscape for ADHD therapeutics is highly competitive, with significant activity in novel compounds, formulations, and prodrugs.
- Companies must conduct thorough freedom-to-operate analyses to navigate existing intellectual property rights.
Frequently Asked Questions
What specific chemical structures are covered by EP3517155?
EP3517155 covers specific amphetamine derivatives defined by a Markush structure, detailing particular substitutions on the aryl and alkyl components of the molecule. The exact structure is detailed in the patent's claims.
Can a competitor develop a generic version of a drug based on EP3517155?
Competitors cannot develop a generic version of a drug based on EP3517155 until the patent and any potential extensions expire, provided the generic version falls within the scope of the patent's claims.
Are there any pending challenges against EP3517155?
As of the most recent public records, there are no publicly disclosed opposition proceedings or invalidity actions filed against EP3517155.
What is the role of formulation claims in EP3517155?
Formulation claims protect specific ways the claimed amphetamine derivatives are prepared into pharmaceutical compositions, such as extended-release tablets or capsules, preventing competitors from using those specific delivery systems.
How does EP3517155 compare to existing amphetamine-based ADHD medications?
EP3517155 claims novel compounds that are chemically distinct from existing widely used amphetamine-based medications like Adderall XR® or Vyvanse®, aiming to offer potentially improved therapeutic profiles.
Citations
[1] European Patent EP3517155. (2019). AMPHETAMINE DERIVATIVES FOR USE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER. European Patent Office.
